FDA's controversial approval of Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy drug Exondys 51 elicited emotional disagreements among FDA staff, but officials maintain that they have largely been put aside.
The decision's effect on FDA morale has been a frequent question, given the internal conflict that ensued during the review....






